Compare Crispr Therapeutics AG (CRSP) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Consumer Staples Select Sector SPDR Fund — how do they compare? Crispr Therapeutics AG trades at $53.99 (market cap $5.22B), while Consumer Staples Select Sector SPDR Fund trades at $86.15. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | XLP | |
|---|---|---|
Market Cap | $5.22B | — |
Sector | Health | — |
52-Week High | $76.78 | $90.00 |
52-Week Low | $44.34 | $75.61 |
Enterprise Value | $3.64B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.99, down 0.15% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by 151% YoY growth in CASGEVY sales to $76 million. Financials show deep losses with a net income margin of -4,101.26% in 2025, though cash flow improved to a net positive $49.30M. Recent news highlights strong analyst optimism and pipeline advancements.
Outlook remains speculative with high growth potential from gene-editing therapies like CASGEVY, but significant risks persist from ongoing losses and clinical trial outcomes. Wall Street consensus is bullish with a $82.67 price target, implying 53% upside, though investors face volatility from earnings misses and cash burn.
XLP trades at $85.08, up 0.46% on the day, with a bullish technical signal driven by moving averages. Analyst consensus is unanimously positive, with 100% buy ratings. The ETF focuses on consumer staples, benefiting from resilient spending trends and defensive positioning amid market volatility, as highlighted in recent earnings reports and sector analysis.
The outlook for XLP is favorable, supported by strong sector fundamentals and defensive demand, though risks include economic sensitivity and competitive ETF offerings. Upside potential hinges on sustained consumer resilience and quality stock leadership shifts, with technical support near $84.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
